|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.|
OPK - Opko Health Inc.
(was EXEG.OB - eXegenics)
3/27/07: Acuity Pharmaceuticals & Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market
2/9/07: eXegenics completed its sale of shares of common stock, constituting approximately 51% of the issued and outstanding shares of eXegenics capital stock, on a fully diluted basis, to a small group of investors led by Phillip Frost, M.D. #msg-18230877 The investors paid eXegenics an aggregate purchase price of $8.6 million at the closing. The purchase price is subject to adjustment based on eXegenics stockholders’ equity at the closing. The shares of eXegenics common stock sold were not registered under the Securities Act of 1933, and may not be offered or sold in the United States absent registration under the Securities Act or the availability of an exemption from registration.
10K filed 3/22/207 showing 36,550,369 shares as of 03/15/2007.
(OLD EXEG IBOX info)
EXEG is a non-operating shell with about $9 million of cash on the books. Outstanding common shares = 17.0 million plus 1.0 million of preferred convertible to common.
The excitement is that Dr. Phillip Frost, a pharmaceutical billionaire, is buying 51% of the stock for cash.
On August 14, 2006, eXegenics, Inc. (the "Company") entered into a Stock Purchase Agreement (the "Purchase Agreement") with a group of investors led by Phillip Frost, M.D, for the sale of shares of the Company's common stock. The shares of common stock to be issued to the purchasers will constitute, upon issuance, 51% of the issued and outstanding shares of common stock of the Company, on a fully-diluted basis. The aggregate purchase price to be paid for the shares is $8,613,000, reflecting the book value of the Company at June 30, 2006
"Investors shall purchase from the Company, an aggregate of 19,440,491" Current outstanding, before the transaction, is
Currently, eXegenics is a shell company. It was formerly known as Cytoclonal Pharmaceutics which was previously involved in researching cancer drugs. However, the co has terminated all research activities. All scientific staff and administrative positions were eliminated. The co has established a committee to study strategic direction and identify potential business opportunities.
Frost is the man behind Ivax Corporation, a generic drug manufacturer,m which was recently acquired by Teva. Frost's company had repeatedly gone to court to fight for the right to produce generic versions of brand-name drugs with expiring patents.
Dr. Phillip Frost was named Vice Chairman of the Board of Teva Pharmaceutical Industries, Ltd. ("Teva") in January 2006 when Teva acquired IVAX Corporation. Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation since 1987. He was Chairman of the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to 1990.
|Go to reply# or date (mm/dd/yy): |
|Go to reply# or date (mm/dd/yy):|
|© 2019 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|